Diabetes Care, Vol 20, Issue 12 1896-1899, Copyright © 1997 by American Diabetes Association

ARTICLES

Serum autoantibodies against sulfatide and phospholipid in NIDDM patients with diabetic neuropathy

H Shigeta, M Yamaguchi, K Nakano, H Obayashi, R Takemura, M Fukui, M Fujii, K Yoshimori, G Hasegawa, N Nakamura, Y Kitagawa and M Kondo
Osaka General Hospital of West Japan Railway Company, Japan.

OBJECTIVE: We investigated the presence of antisulfatide and antiphospholipid antibodies and the relationship between these antibodies and the results of quantitative tests of nerve function in NIDDM patients with diabetic neuropathy. RESEARCH DESIGN AND METHODS: Antisulfatide and antiphospholipid antibodies were measured in serum samples obtained from 68 NIDDM patients with diabetic neuropathy by an enzyme-linked immunosorbent assay (ELISA). Each patient was classified into one of three groups based on the combined neuropathy score (determined by the symptom score, the results of autonomic nerve function tests, and the vibration perception test), as follows: mild (n = 26), moderate (n = 22), and severe (n = 20). Nerve conduction studies were performed in a subgroup of 37 patients. RESULTS: The antisulfatide antibody was detected in 1 (4%) of 26 patients in the mild group, 4 (18%) of 22 patients in the moderate group, and 8 (40%) of 20 patients in the severe group (P < 0.01 vs. mild group). The antiphospholipid antibody was detected in none of the patients in the mild group, 8 (36%) of 22 patients in the moderate group (P < 0.001 vs. mild group), and 6 (30%) of 20 patients in the severe group (P < 0.01 vs. mild group). The threshold amplitude, determined by the vibration perception test, was significantly higher in antibody-positive patients than in antibody-negative patients: antisulfatide antibody, 55.9 +/- 46.8 microns (n = 13) vs. 22.9 +/- 13.7 microns (n = 55), P < 0.001; antiphospholipid antibody, 47.2 +/- 32.5 microns (n = 14) vs. 24.5 +/- 23.2 microns (n = 54), P < 0.01. The conduction velocity of the sural nerve was slower in the antisulfatide antibody-positive group (37.9 +/- 11.1 m/s, n = 12) than in the antisulfatide antibody-negative group (45.2 +/- 6.0 m/s, n = 19) (P < 0.05). CONCLUSIONS: These results suggest that autoimmune nerve destruction may be involved in diabetic neuropathy in NIDDM patients.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K C Gorson and A H Ropper Additional causes for distal sensory polyneuropathy in diabetic patients. J. Neurol. Neurosurg. Psychiatry, March 1, 2006; 77(3): 354 - 358. [Abstract] [Full Text] [PDF]

				A. I. Vinik, D. Anandacoomaraswamy, and J. Ullal Antibodies to Neuronal Structures: Innocent bystanders or neurotoxins? Diabetes Care, August 1, 2005; 28(8): 2067 - 2072. [Full Text] [PDF]

				K. R. Sharma, J. Cross, O. Farronay, D. R. Ayyar, R. T. Shebert, and W. G. Bradley Demyelinating Neuropathy in Diabetes Mellitus Arch Neurol, May 1, 2002; 59(5): 758 - 765. [Abstract] [Full Text] [PDF]

				E. Akarsu, I. Pirim, I. Çapoglu, O. Deniz, G. Akçay, and N. Ünüvar Relationship Between Electroneurographic Changes and Serum Ubiquitin Levels in Patients With Type 2 Diabetes Diabetes Care, January 1, 2001; 24(1): 100 - 103. [Abstract] [Full Text]

				R. Dabby, L. H. Weimer, A. P. Hays, M. Olarte, and N. Latov Antisulfatide antibodies in neuropathy: Clinical and electrophysiologic correlates Neurology, April 11, 2000; 54(7): 1448 - 1452. [Abstract] [Full Text] [PDF]

				R. Brey and A. Escalante Review : Neurological manifestations of antiphospholipid antibody syndrome Lupus, January 1, 1998; 7(2_suppl): S67 - S74. [Abstract] [PDF]